Monopar Therapeutics Inc Stock price
Compare with Peer Group
Is Monopar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Monopar Therapeutics Inc Stock Analysis
Analyst Opinions
19 Analysts have issued a Monopar Therapeutics Inc forecast:
Analyst Opinions
19 Analysts have issued a Monopar Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Monopar Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monopar Therapeutics Inc Stock News
Company Profile
Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
| Head office | United States |
| CEO | Dr. Robinson |
| Employees | 22 |
| Founded | 2014 |
| Website | www.monopartx.com |


